First Time Loading...

Evaxion Biotech A/S
NASDAQ:EVAX

Watchlist Manager
Evaxion Biotech A/S Logo
Evaxion Biotech A/S
NASDAQ:EVAX
Watchlist
Price: 3.91 USD -1.01%
Updated: May 7, 2024
Section:
 

Wall Street
Price Targets

EVAX Price Targets Summary
Evaxion Biotech A/S

Wall Street analysts forecast EVAX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EVAX is 11.99 USD with a low forecast of 7.07 USD and a high forecast of 18.9 USD.

EVAX Lowest Forecast
Wall Street Target
7.07 USD
81% Upside
EVAX Average Forecast
Wall Street Target
11.99 USD
207% Upside
EVAX Highest Forecast
Wall Street Target
18.9 USD
383% Upside
Lowest
Price Target
7.07 USD
81% Upside
Average
Price Target
11.99 USD
207% Upside
Highest
Price Target
18.9 USD
383% Upside
Evaxion Biotech A/S Competitors:
Price Targets
J
7774
Japan Tissue Engineering Co Ltd
96% Upside
K
2162
KeyMed Biosciences Inc
74% Upside
9966
Alphamab Oncology
66% Upside
OCGN
Ocugen Inc
255% Upside
J
7774
Japan Tissue Engineering Co Ltd
96% Upside
K
2162
KeyMed Biosciences Inc
74% Upside
9966
Alphamab Oncology
66% Upside
OCGN
Ocugen Inc
255% Upside
GILD
Gilead Sciences Inc
29% Upside
N
4893
Noile-Immune Biotech Inc
186% Upside
HALO
Halozyme Therapeutics Inc
27% Upside
M
MAAT
Maat Pharma SA
68% Upside

Revenue
Forecast

Revenue Estimate
Evaxion Biotech A/S

The compound annual growth rate of Evaxion Biotech A/S's revenue for the next 3 years is 861%.

N/A
Past Growth
861%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Evaxion Biotech A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Evaxion Biotech A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-54%
Average Miss
What are analyst estimates?

See Also

Summary
EVAX intrinsic value, competitors valuation, and company profile.
DCF Valuation
EVAX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EVAX stock valuation using valuation multiples.
Wall Street Estimates
EVAX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EVAX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EVAX's stock price target?
Price Target
11.99 USD

According to Wall Street analysts, the average 1-year price target for EVAX is 11.99 USD with a low forecast of 7.07 USD and a high forecast of 18.9 USD.

What is Evaxion Biotech A/S's Revenue forecast?
Projected CAGR
861%

The compound annual growth rate of Evaxion Biotech A/S's revenue for the next 3 years is 861%.

ALPHA SPREAD
Join more than 135,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.